Kornimate/medical-research-clean huggingface dataset:
liquid biopsy for early non-small lung cancer detection

Conditions: Non Small-cell Lung Cancer

Summary: this clinical trial will assess the performance of a liquid biopsy assay to identify cancer in indeterminant pulmonary nodules identified by ct screening of high-risk individuals and evaluate the capability of the liquid biopsy assay to monitor response to surgical resection.

this clinical study examines the feasibility of a liquid biopsy methylation assay to detect non-small lung cancer. first, the investigators will apply their liquid biopsy assay to screen for lung cancer in indeterminate pulmonary nodules suspicious for cancer. second, the investigators will assess the utility of liquid biopsy to assess tumor dynamics after surgical resection with curative intent. third, the investigators will assess the presence or absence of this methylation assay in healthy normal persons without a history of lung cancer.

Eligibility criteria:
indeterminate pulmonary nodule study cohort * inclusion criteria: patients undergoing a biopsy of an indeterminate lung nodule by surgical excision, bronchoscopic biopsy or interventional radiology directed biopsy * exclusion criteria: no known concurrent cancer known lung cancer for surgical resection study cohort * inclusion criteria: patients with known non-small cell lung cancer who will have surgical resection for treatment * exclusion criteria: n/a healthy volunteer cohort * inclusion criteria: healthy persons * exclusion criteria: no known current cancer or history of cancer within 5 years benign lung disease cohort * inclusion criteria: patients with the following categories of benign lung disease: copd/emphysema, granulomatous infection, interstitial lung disease including pulmonary fibrosis and interstitial lung disease. * exclusion criteria: n/a

Keywords: lung cancer biomarker dna methylation
the 3d reconstruction research of pelvic organ prolapse disease

Conditions: Pelvic Organ Prolapse; Normal Pelvic Floor

Summary: female pelvic organ prolapse (fpop) is one of the main diseases affecting the quality of life of middle aged and elderly women in non-neoplastic diseases. an aging population makes the incidence of this disease to increase year by year. surgical operation is the main treatment. while the recurrence rate of classic repair surgery is high, the method of patch implantation reinforces the supporting force, which significantly reduce the recurrence rate. however, this method is costly and is associated with complications which may trigger new symptoms. as such, there is still no perfect surgical method. the main reason for this is that the assessment method of pelvic defects is crude and indirect, which results in the diagnosis of fpop only representing external problems whereas, inner defected parts are not properly assessed. in recent years, research with the use of 2d and 3d mri reconstructions on the anus levator muscle and ligament has become a hot topic. it found that the characteristic of the high resolution of soft tissue in the magnetic resonance imaging (mri) has a big advantage in pelvic floor study.the investigators commenced the study of 3d reconstruction technology based on the mri datasets in 2009. the investigators have mastered the most common, key technologies of mri three-dimensional reconstruction. the investigators have done research targeted on the reconstruction methods of the normal pelvis, viscera, ligaments, pelvic floor muscles. this project is aimed at 3d reconstruction of the whole pelvic base on static and dynamic mri images from fpop patients, and establish the corresponding space coordinates assessment system to do location and quantitative research of the pelvic viscera and its support structure, thus providing a fpop diagnosis platform that is more precise, direct and comprehensive.


Eligibility criteria:
inclusion criteria: 1. female who were diagnosed with pelvic organ prolapse by using pelvic organ prolapse quantification (pop-q) exams; 2. without history of pelvic surgery; 3. could cooperate smoothly with valsalva maneuver. exclusion criteria: 1. combined with gynecologic malignant tumors； 2. with mri contraindications； 3. female who refuse to undergo mri evaluation.

Keywords: pelvic organ prolapse dynamic magnetic resonance imaging three-dimensional reconstruction space coordinates
a study to optimize care for lung cancer patients undergoing video-assisted thoracoscopic surgery (vats)

Conditions: Lung Cancer

Summary: this is a research study for participants who have been diagnosed with lung cancer and are receiving vats (video assisted thoracoscopic surgery) lobectomy or segmentectomy. the overall objective of this study is to develop a database to collect data on participants who are undergoing vats lobectomy or segmentectomy for lung cancer.

this database will be used as for quality improvement purposes. furthermore, the database will help in collecting data in an organized fashion, which will help the investigators learn more about the details of the workup performed prior to the surgery, during the surgery, peri-operative management and early follow-up. the investigators hope that this database will help to determine a common guideline to perform vats lobectomy or segmentectomy. by creating a common guideline for future treatment of vats patients, the investigators predict the efficiency of the process will increase significantly without decreasing, and perhaps even improving, the quality of the procedure.

Eligibility criteria:
inclusion criteria: * male and female subjects * age ≥ 18 years * underwent a vats lobectomy or segmentectomy procedure for lung cancer -- note: patients with other malignancies are eligible if they have a primary cancer of the lung as defined above exclusion criteria: * subjects undergoing thoracotomy lobectomy or segmentectomy for lung cancer * subjects undergoing surgical procedures other than vats lobectomy or segmentectomy for lung cancer

Keywords: vats lobectomy and segmentectomy for lung cancer lung cancer
increasing physical activity in older adults with osteoarthritis pain: examining a brief behavioral intervention

Conditions: Osteoarthritis, Knee; Osteoarthritis, Hip

Summary: the purpose of this study is to evaluate how older adults might benefit from sessions that teach behavioral coping skills for increasing physical activity and reducing interference from arthritis pain. this study will randomize individuals to receive engage-pa, or continue to receive treatment as usual. engage-pa involves two sessions (about 45 minutes each) with a study therapist that teaches individuals behavioral skills for increasing daily steps. these behavioral skills include identifying their personal values and instructions on how to pace their daily physical activity to avoid creating severe pain when walking. all participants in the study will wear small devices that track physical activity such as daily steps throughout the study, which also allow participants to see their daily step counts and overall level of activity. all participants will answer a set of questions about how much arthritis gets the way of many important life activities, their success at living in line with their personal values, and how much thoughts, feelings and body sensations get in the way of living a satisfying life. these questions will be asked at the beginning of the study and 6 weeks into the study.


Eligibility criteria:
inclusion criteria: * age 65 or older * english speaking * diagnosis of osteoarthritis in knee or hip * able to ambulate even if assisted with ambulatory device such as walker or cane * endorse worst pain and pain interference as ≥ 3 out of 10 within the last week exclusion criteria: * planned surgery during study duration that would limit mobility (e.g., due to recommended rehabilitation or recovery period) for more than 3 weeks * current enrollment in cardiac rehabilitation * myocardial infarction in the past 3 months * major surgery requiring limited movement or mobility for recovery within the past 3 months * presence of a serious psychiatric condition (e.g., schizophrenia, suicidal intent) indicated by medical chart, treating medical provider or other staff, or study staff interactions that would contraindicate safe study participation * medical provider indicating that exercise (even walking) should only be medically supervised; as determined by medical record review or patient reported * fall or falls within the last 3 months that led to immediate medical treatment/hospitalization * reported or suspected moderate or severe cognitive impairment subsequently informed by a folstein mini-mental status examination of \<19

Keywords: engage pa treatment as usual
a study to look at how insulin nnc0471-0119 works in the body in people with type 1 diabetes when injected by insulin pump

Conditions: Diabetes Mellitus, Type 1

Summary: this study is looking at the effect and safety of 3 formulations of the new rapid-acting insulin analogue nnc0471-0119, for the treatment of type 1 diabetes when given by insulin pump. the study will test how 3 different formulations of insulin nnc0471-0119 are tolerated by the body, how they are transported in participants bloodstream, how long they stay there and how the blood sugar is lowered. the 3 formulations of insulin nnc0471-0119 are given as one bolus on top of a constant insulin basal rate and compared to faster aspart (fiasp®). participants will get 3 formulations of insulin nnc0471-0119 and faster aspart (fiasp®) insulin nnc0471-0119 is a new rapid-acting insulin designed to be used in an insulin pump. faster aspart (fiasp®) is a globally used medication for the treatment of diabetes. participants will have each study medicine administered once via pump at separate study visits. this mean that participants will have a total of 4 dosing visits where participants will get a study medicine. which study medicine participants get at what visit will be decided by chance. the study will last 1-4 months. participants will have 7 visits at the clinic, 4 of them will require an in-house stay of 3 consecutive days each. during the in-house visits 2 intravenous (into the vein) cannulas will be inserted for blood sampling and infusions. women: women cannot take part if they are of childbearing potential.


Eligibility criteria:
inclusion criteria: * male participant or female participant of non-childbearing potential. non-childbearing potential being defined as surgically sterilised (i.e. documented hysterectomy, bilateral salpingectomy or bilateral oophorectomy) or being postmenopausal (defined as no menses for 12 months without an alternative medical cause) prior to the day of screening. * aged 18-64 years (both inclusive) at the time of signing informed consent. * diagnosed with t1dm for more than1 year prior to the day of screening. * current total daily insulin treatment between 0.2 and 1.2 (i)u/kg/day (both inclusive). * treated with continuous subcutaneous insulin infusion greater than 90 days prior to the day of screening. exclusion criteria: * known or suspected hypersensitivity to study interventions or related products. * participation (i.e., study intervention) in any interventional, clinical study within 30 days or 5 times the half-life of the drug, whichever is longest before screening.
behaviour after exercise of biological, clinical and metabolic variables as from different temperatures and times of immersion cold water application

Conditions: Cryotherapy Effect

Summary: introduction: immersion cold water is a recuperative strategy commonly used, however, are not yet fully understood the real effects of this technique on specific conditions. objective: to analyze and to compare the effects of the immersion cold water during the intense post-exercise recovery, using different times and temperatures on biological, clinical and metabolic variables. method: 105 male subjects were divided into five groups: one control group (cg) and four recoveries (g1: 5' at 9±1 degrees celsius; g2: 5' at 14±1 degrees celsius; g3: 15' at 9±1 degrees celsius; g4: 15' at 14±1 degrees celsius). the volunteers were submitted an exhaustion protocol that consisted of a program of jumps and the wingate test. immediately after the exhaustion protocol, volunteers were directed to a tank with water and ice, which were immersed up to the height of the anterior superior iliac spine to the recovery procedure, during which blood samples were collected for later analysis lactate and creatine kinase (ck). variables were collected prior to the exercise, 24, 48, 72 and 96 hours after the end of it. furthermore, the perception of pain and recovery of the lower limbs were also collected at specific moments by means respectively of the likert scale of perceived effort and visual analogue scale pain. appropriate statistical analysis was used to compare the groups and the moments, considering the 5% level of significance.


Eligibility criteria:
inclusion criteria: * male sex * healthy * aged between 18 and 30 years * classified as physically active through the international physical activity questionnaire exclusion criteria: * anemia * inflammation * diabetes * cardiovascular disease * liver problems * alcoholics * smokers * illicit drug users * chronic users of anti-inflammatory drugs * episode of musculotendinous or osteoarticular injury in the lower and/or column members during the last six months.

Keywords: immersion recovery of function lactate creatine kinase musculoskeletal pain
phase ii study of anlotinib in patients with advanced non-small cell lung cancer（alter0302）

Conditions: Non-small Cell Lung Cancer

Summary: anlotibib (al3818) is a kind of innovative medicines approved by state food and drug administration（sfda:2011l00661） which was researched by jiangsu chia-tai tianqing pharmaceutical co., ltd. anlotinib is a kinase inhibitor of receptor tyrosine with multi-targets, especially for vegfr2、vegfr3、pdgfrβ and c-kit. it has the obvious resistance to new angiogenesis. the trial is to explore anlotinib for the effectiveness and safety of andvanced non-small cell lung cancer who failed two lines of chemotherapy


Eligibility criteria:
inclusion criteria: 1. pathology diagnosed with advanced nscl with measurable lesions; 2. have failed for 2 lines of chemotherapy; 3. 18-70years,ecog ps:0-2,life expectancy of more than 3 months; 4. other cytotoxic drugs,radiation therapy,or surgery≥4 weeks; 5. main organs function is normal; 6. must be agreed to take contraceptive measures during the study and within 6 months after end. exclusion criteria: 1. sclc(including mixed with nsclc); 2. the central cavity of squamous cell carcinoma and hemoptysis with nsclc; 3. patients failed to use the anti-tumor angiogenesis therapy; 4. patients has many influence factors toward oral medications ; 5. brain metastases patients accompanied by symptoms or symptom control for less than two months; 6. patients with severe and failed to controlled diseases,including: suboptimal blood pressure control;suffering from myocardial ischemia or above grade i myocardial infarction, arrhythmias and class i heart failure;activity or failure to control severe infections;liver disease such as cirrhosis, decompensated liver disease, chronic active hepatitis;poorly controlled diabetes (fbg)\>10mmol/l);urine protein≥++,etc. 7. patients failed to heal wounds or fractures for long-term; 8. 4 weeks before enrollment, patients appeared nci ctc ae grading \>1 pulmonary hemorrhage; 4 weeks before enrollment, patients who appeared nci ctc ae grade\> 2 have other parts of the bleeding; patients has a tendency to bleed (eg active peptic ulcer) or are receiving thrombolytic or anticoagulant therapy such as warfarin, heparin or its analogues; 9. patients occurred venous thromboembolic events within 6 months; 10. patients has hiv-positive or organ transplantation;

Keywords: lung anlotinib al3818 nsclc cancer
multidrug blister pack study

Conditions: Any Event Leading to Hospitalisation

Summary: the purpose of this study is to determine the benefit of patients using a multidrug blister packs after discharged from an university hospital to their homes.

typical adherence rates for oral prescription medications are approximately 50-76%. insufficient adherence causes an increase in morbidity, mortality, and costs, and decreases quality of life of patients. multidrug blister packs are recommended to improve adherence and are widely used in switzerland. however, evidence is poor and patient-relevant endpoints are seldom measured. this study was designed to compare patient-relevant outcomes in patients with medication repackaged in multidrug blister packs versus patients with medication dispensed in commercially available packages. adherence of the intervention group will be monitored electronically and feedback will be given to the patients. the intervention will take place in a study pharmacy. follow-up visits will take place at the study pharmacy at 3, 6, and 12 months for all patients. study duration will be 12 months.

Eligibility criteria:
inclusion criteria: * age over 18 years * prescription of 4 or more different oral solid drugs * capable to understand german (verbally and written) * capable to give informed consent * insured by a swiss health insurance * manages his/her pharmacotherapy without external support * obtains his/her medication from a community pharmacy * accepts to use an electronic multidrug blister pack * place of domicile in basel-stadt or basel-land exclusion criteria: * pregnancy * \> 2 drugs that cannot be packed into a multidrug blister pack (e.g. fluids) * dementia, or evaluated as cognitively impaired by the responsible nurse * transplanted patient * anticoagulation with oral vitamin k antagonists * has already used a multidrug blister pack of pharmis or a medifilm® single dose system * is visually impaired (blind) * cannot push drugs through a blister * refuses to allow contact to his/her regular pharmacy and gp * is referred to a nursing home or to rehabilitation or another hospital at discharge * is included in other clinical trial

Keywords: adherence electronic monitoring primary care community pharmacy multidrug blister pack pill box
reconstruction of upper eyelid with a newly modified cutler-beard technique with tarsoconjunctival graf

Conditions: Reconstructive Surgical Procedure

Summary: to study the results of a modified cutler-beard technique , using a contralateral tarsoconjunctival graft, in patients who underwent excision of large malignant tumors of the upper eyelid

a tarsoconjunctival graft was harvested from the contralateral upper eyelid, with an extra 3 mm of conjunctiva from the superior edge of tarsus and was attached to the upper eyelid defect, differently than previously described. functional, cosmetic outcomes and postoperative complications were evaluated.

Eligibility criteria:
inclusion criteria: * upper eyelid defect after tumor resection exclusion criteria: * previous surgery

Keywords: cutler-beard tarsoconjunctival graft upper eyelid
intensive sequential chemotherapy with adriamycin taxol and cytoxan in the treatment of locally advanced breast cancer

Conditions: Breast Cancer

Summary: intensive sequential chemotherapy with adriamycin taxol and cytoxan in the treatment of locally advanced breast cancer


Eligibility criteria:
inclusion criteria: * patients with locally advanced breast cancer
registry on watchman outcomes in real-life utilization wasp registry

Conditions: Atrial Fibrillation

Summary: this is an observational, prospective, non-randomized, multicenter study with the following objectives: (1) to compile real-world clinical outcomes data for watchman left atrial appendage closure technology in patients who are implanted with the watchman device in a commercial clinical setting and (2) to collect health care usage data that may be needed for reimbursement of watchman technology in certain countries.

approximately 200 subjects will be enrolled in the study. up to 10 sites in the asia pacific and middle east regions will participate. primary analyses may include, but will not be limited to, the following: procedural complications, incidence of stroke and death. descriptive statistics will be used for baseline, procedure and follow-up data collected through the study. each patient will be followed for a period of two years after implant according to the schedule and standard practice at the enrolling centers. there will be no additional visits, nor procedures, for subjects who participate in the study. subjects are expected to be followed at implant, then at one post-implant visit (typically between 1-3 months of implant), and then annually through 2 years post implant. an intermediate visit may be scheduled in a number of patients, per physician discretion. in order to reliably capture patient status at study end, a follow-up window of 24 +/- 3 months will be considered acceptable for scheduling the last visit. for subjects who are not scheduled to visit the clinical for a follow-up, a subject contact (e.g. phone call) will ensure capture of the endpoint related information; however, it is recommended to perform an in-office visit for at least the first annual visit. enrollment is expected to be completed in 21 months; therefore the total study duration is estimated to be 48 months.

Eligibility criteria:
inclusion criteria: * patients who are eligible for a watchman device according to current international and local guidelines (and future revisions) and per physician discretion; * patients who are willing and capable of providing informed consent, participating in all testing associated with this clinical investigation at an approved clinical investigational center; * patients whose age is 18 years or above, or of legal age to give informed consent specific to state and national law. exclusion criteria: * patients who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the patient is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments. each instance should be brought to the attention of the sponsor to determine eligibility. * women of childbearing potential who are, or plan to become, pregnant during the time of the study (method of assessment upon physician's discretion); * the subject is unable or not willing to complete follow-up visits and examination for the duration of the study.